patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_849378 | REC_0016201 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 33 | 9.4 | 73 | female | 1 | 28 | 5.6 | 2 | carboplatin + paclitaxel + pembrolizumab | 25.2 | true | MSS | 2026-03-15T05:36:01.644630+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_269286 | REC_0016202 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 14.4 | 60 | male | 0 | 14 | 4 | 4 | sotorasib 960 mg daily | 21.7 | false | MSS | 2026-03-15T05:36:01.645006+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_961994 | REC_0016203 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 10.1 | 63 | male | 1 | 14 | 6.8 | 6 | osimertinib 80 mg daily | 18.1 | false | MSS | 2026-03-15T05:36:01.645358+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_626630 | REC_0016204 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 29 | 15.4 | 74 | female | 1 | 16 | 5.4 | 7 | pembrolizumab 200 mg q3w | 9.8 | false | MSS | 2026-03-15T05:36:01.645745+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_233902 | REC_0016205 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 7.5 | 62 | female | 0 | 19 | 5.3 | 5 | entrectinib 600 mg daily | 13.3 | true | MSS | 2026-03-15T05:36:01.646083+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_822900 | REC_0016206 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 33 | 5.1 | 60 | female | 1 | 8 | 5.8 | 4 | pembrolizumab 200 mg q3w | 11 | true | MSS | 2026-03-15T05:36:01.646411+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_913307 | REC_0016207 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 12 | 62 | female | 0 | 8 | 5.8 | 1 | alectinib 600 mg BID | 14.9 | false | MSS | 2026-03-15T05:36:01.646728+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_812460 | REC_0016208 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 16.5 | 66 | female | 1 | 19 | 6.7 | 5 | sotorasib 960 mg daily | 17.6 | false | MSI-H | 2026-03-15T05:36:01.647048+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_999731 | REC_0016209 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 14.3 | 64 | female | 1 | 13 | 7.1 | 4 | alectinib 600 mg BID | 14.1 | false | MSI-H | 2026-03-15T05:36:01.647349+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_956649 | REC_0016210 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 11.9 | 85 | female | 1 | 14 | 3.6 | 6 | alectinib 600 mg BID | 14.6 | true | MSS | 2026-03-15T05:36:01.647652+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_530348 | REC_0016211 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 15 | 13.4 | 74 | female | 2 | 16 | 7.3 | 7 | entrectinib 600 mg daily | 7.4 | false | MSI-H | 2026-03-15T05:36:01.647982+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_718635 | REC_0016212 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 12.9 | 53 | male | 0 | 18 | 3.5 | 7 | osimertinib 80 mg daily | 15.4 | true | MSS | 2026-03-15T05:36:01.648591+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_998989 | REC_0016213 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 15.8 | 76 | male | 2 | 22 | 5.7 | 6 | entrectinib 600 mg daily | 14.4 | true | MSI-H | 2026-03-15T05:36:01.649042+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_328947 | REC_0016214 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 9.4 | 85 | female | 2 | 11 | 7.2 | 5 | osimertinib 80 mg daily | 14.5 | false | MSS | 2026-03-15T05:36:01.649415+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_810264 | REC_0016215 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 29 | 5.8 | 77 | female | 1 | 16 | 5.4 | 7 | pembrolizumab 200 mg q3w | 16.1 | false | MSS | 2026-03-15T05:36:01.649748+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_890308 | REC_0016216 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 10.1 | 64 | male | 0 | 18 | 5.1 | 5 | osimertinib 80 mg daily | 10 | true | MSS | 2026-03-15T05:36:01.650086+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_572864 | REC_0016217 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 8.4 | 57 | male | 1 | 15 | 5.9 | 6 | osimertinib 80 mg daily | 12.1 | true | MSS | 2026-03-15T05:36:01.650443+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_354819 | REC_0016218 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 11.5 | 66 | female | 0 | 0 | 3.7 | 6 | alectinib 600 mg BID | 11.3 | true | MSI-H | 2026-03-15T05:36:01.650789+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_432503 | REC_0016219 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 5.4 | 57 | female | 0 | 36 | 4.2 | 2 | carboplatin + paclitaxel + pembrolizumab | 15.2 | true | MSS | 2026-03-15T05:36:01.651141+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_755790 | REC_0016220 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 20 | 10 | 72 | male | 0 | 20 | 4.8 | 2 | pembrolizumab 200 mg q3w | 15.1 | false | MSS | 2026-03-15T05:36:01.651494+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_717683 | REC_0016221 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 33 | 9 | 50 | female | 0 | 28 | 5.8 | 5 | osimertinib 80 mg daily | 15.3 | true | MSS | 2026-03-15T05:36:01.651852+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_326026 | REC_0016222 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 5.3 | 59 | female | 1 | 82 | 7.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 25.2 | true | MSS | 2026-03-15T05:36:01.652268+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_128266 | REC_0016223 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 12 | 52 | male | 0 | 11 | 5.8 | 1 | osimertinib 80 mg daily | 19.1 | false | MSI-H | 2026-03-15T05:36:01.652654+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_333303 | REC_0016224 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 7.1 | 53 | female | 0 | 27 | 5.9 | 2 | carboplatin + paclitaxel + pembrolizumab | 21.3 | false | MSS | 2026-03-15T05:36:01.653051+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_966675 | REC_0016225 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 11.2 | 71 | male | 2 | 19 | 6.9 | 3 | pembrolizumab 200 mg q3w | 15.9 | true | MSS | 2026-03-15T05:36:01.653603+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_757600 | REC_0016226 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 16.4 | 77 | male | 0 | 12 | 4.2 | 6 | entrectinib 600 mg daily | 13.9 | true | MSI-H | 2026-03-15T05:36:01.654048+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_275122 | REC_0016227 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 39 | 9.2 | 74 | female | 1 | 13 | 4.9 | 1 | alectinib 600 mg BID | 24.1 | false | MSS | 2026-03-15T05:36:01.654363+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_434051 | REC_0016228 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 4.3 | 64 | female | 0 | 9 | 4.3 | 7 | sotorasib 960 mg daily | 5.6 | false | MSS | 2026-03-15T05:36:01.654682+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_604988 | REC_0016229 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 10.9 | 58 | male | 1 | 10 | 4.8 | 1 | osimertinib 80 mg daily | 4.6 | false | MSI-H | 2026-03-15T05:36:01.655012+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_926391 | REC_0016230 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 19 | 5.8 | 68 | male | 0 | 64 | 5.2 | 2 | carboplatin + paclitaxel + pembrolizumab | 13.4 | true | MSS | 2026-03-15T05:36:01.655329+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_650774 | REC_0016231 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 13.8 | 79 | male | 1 | 19 | 5.4 | 1 | alectinib 600 mg BID | 25.1 | true | MSI-H | 2026-03-15T05:36:01.655659+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_620256 | REC_0016232 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 13.2 | 61 | female | 1 | 26 | 5 | 5 | entrectinib 600 mg daily | 15.6 | false | MSS | 2026-03-15T05:36:01.655999+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_466830 | REC_0016233 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 14.3 | 90 | female | 2 | 18 | 4.5 | 6 | entrectinib 600 mg daily | 16.1 | true | MSI-H | 2026-03-15T05:36:01.656393+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_967718 | REC_0016234 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 17.7 | 61 | male | 0 | 35 | 5.5 | 1 | osimertinib 80 mg daily | 14.7 | false | MSS | 2026-03-15T05:36:01.656717+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_344195 | REC_0016235 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 18 | 11.2 | 51 | male | 0 | 4 | 5.6 | 5 | sotorasib 960 mg daily | 9 | false | MSS | 2026-03-15T05:36:01.656992+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_113503 | REC_0016236 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 18 | 63 | male | 1 | 9 | 3.8 | 4 | sotorasib 960 mg daily | 7.8 | false | MSS | 2026-03-15T05:36:01.657246+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_289292 | REC_0016237 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 32 | 6.6 | 73 | female | 1 | 21 | 5.9 | 2 | sotorasib 960 mg daily | 28.4 | true | MSS | 2026-03-15T05:36:01.657491+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_865444 | REC_0016238 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 16.7 | 66 | female | 1 | 14 | 6.3 | 6 | sotorasib 960 mg daily | 17.8 | true | MSI-H | 2026-03-15T05:36:01.657890+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_293651 | REC_0016239 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 16.1 | 87 | female | 2 | 20 | 5.3 | 2 | osimertinib 80 mg daily | 23.7 | true | MSI-H | 2026-03-15T05:36:01.658211+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_307395 | REC_0016240 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 7 | 74 | female | 2 | 18 | 6.8 | 8 | alectinib 600 mg BID | 11.4 | false | MSS | 2026-03-15T05:36:01.658522+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_958509 | REC_0016241 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 20.7 | 61 | female | 1 | 9 | 5.8 | 5 | osimertinib 80 mg daily | 11.2 | false | MSI-H | 2026-03-15T05:36:01.658808+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_848990 | REC_0016242 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 13.1 | 65 | female | 0 | 18 | 6.1 | 4 | alectinib 600 mg BID | 11.7 | true | MSS | 2026-03-15T05:36:01.659080+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_703875 | REC_0016243 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 10.1 | 65 | female | 1 | 32 | 4.5 | 2 | alectinib 600 mg BID | 13.8 | true | MSS | 2026-03-15T05:36:01.659359+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_764460 | REC_0016244 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 12.2 | 76 | female | 0 | 6 | 4.3 | 1 | entrectinib 600 mg daily | 24 | true | MSI-H | 2026-03-15T05:36:01.659649+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_168915 | REC_0016245 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 33 | 5.7 | 65 | male | 0 | 25 | 4.2 | 6 | pembrolizumab 200 mg q3w | 7.8 | true | MSS | 2026-03-15T05:36:01.659952+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_803873 | REC_0016246 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 11.9 | 49 | female | 0 | 17 | 3.6 | 5 | entrectinib 600 mg daily | 16.8 | false | MSS | 2026-03-15T05:36:01.660334+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_707434 | REC_0016247 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 10.5 | 68 | female | 1 | 17 | 4.6 | 1 | alectinib 600 mg BID | 16.3 | true | MSS | 2026-03-15T05:36:01.660674+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_291540 | REC_0016248 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 6.9 | 66 | female | 1 | 27 | 5.2 | 3 | carboplatin + paclitaxel + pembrolizumab | 16.4 | false | MSS | 2026-03-15T05:36:01.661033+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_904695 | REC_0016249 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 17 | 13.9 | 69 | female | 0 | 12 | 7.6 | 3 | sotorasib 960 mg daily | 27.5 | false | MSS | 2026-03-15T05:36:01.661389+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_676862 | REC_0016250 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 12.8 | 70 | female | 2 | 12 | 5.5 | 5 | sotorasib 960 mg daily | 11.4 | true | MSI-H | 2026-03-15T05:36:01.661716+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_659368 | REC_0016251 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 14.2 | 81 | female | 2 | 12 | 6.8 | 6 | entrectinib 600 mg daily | 6.6 | true | MSI-H | 2026-03-15T05:36:01.662208+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_954324 | REC_0016252 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 17.8 | 67 | female | 0 | 28 | 4.6 | 5 | osimertinib 80 mg daily | 13 | false | MSI-H | 2026-03-15T05:36:01.662574+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_734467 | REC_0016253 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 26 | 4.9 | 70 | female | 2 | 45 | 5.5 | 2 | pembrolizumab 200 mg q3w | 21.5 | true | MSS | 2026-03-15T05:36:01.662937+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_702004 | REC_0016254 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 32 | 12.5 | 67 | male | 0 | 0 | 8.2 | 5 | osimertinib 80 mg daily | 11.5 | true | MSS | 2026-03-15T05:36:01.663650+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_138775 | REC_0016255 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 26 | 8.5 | 68 | female | 0 | 19 | 6.6 | 6 | pembrolizumab 200 mg q3w | 8.5 | true | MSS | 2026-03-15T05:36:01.663983+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_743886 | REC_0016256 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 6.8 | 71 | female | 1 | 18 | 5.1 | 5 | entrectinib 600 mg daily | 10.9 | false | MSS | 2026-03-15T05:36:01.664407+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_472725 | REC_0016257 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 13 | 14.8 | 68 | female | 0 | 12 | 5.4 | 7 | osimertinib 80 mg daily | 12.3 | true | MSS | 2026-03-15T05:36:01.664814+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_371087 | REC_0016258 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 8.1 | 84 | female | 2 | 21 | 3.6 | 7 | alectinib 600 mg BID | 16.7 | true | MSS | 2026-03-15T05:36:01.665322+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_485393 | REC_0016259 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 5.8 | 57 | male | 0 | 0 | 5.9 | 1 | carboplatin + paclitaxel + pembrolizumab | 13.4 | true | MSS | 2026-03-15T05:36:01.665767+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_395154 | REC_0016260 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 35 | 6.4 | 87 | female | 2 | 29 | 6.6 | 6 | carboplatin + paclitaxel + pembrolizumab | 13.2 | true | MSS | 2026-03-15T05:36:01.666195+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_187159 | REC_0016261 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 32 | 7.4 | 77 | male | 1 | 27 | 6 | 6 | alectinib 600 mg BID | 4 | false | MSS | 2026-03-15T05:36:01.666572+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_366665 | REC_0016262 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 31 | 11.4 | 63 | female | 1 | 22 | 5 | 2 | entrectinib 600 mg daily | 5.3 | true | MSS | 2026-03-15T05:36:01.666953+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_347619 | REC_0016263 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 11 | 71 | male | 1 | 14 | 8.6 | 5 | entrectinib 600 mg daily | 8.4 | false | MSI-H | 2026-03-15T05:36:01.667329+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_467238 | REC_0016264 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 18 | 76 | male | 2 | 18 | 3.3 | 7 | osimertinib 80 mg daily | 7.3 | false | MSI-H | 2026-03-15T05:36:01.667929+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_821945 | REC_0016265 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 13.3 | 71 | female | 1 | 22 | 7.9 | 1 | entrectinib 600 mg daily | 14 | false | MSS | 2026-03-15T05:36:01.668473+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_298107 | REC_0016266 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 20 | 12.2 | 74 | female | 2 | 0 | 6.6 | 1 | osimertinib 80 mg daily | 22.1 | false | MSI-H | 2026-03-15T05:36:01.668869+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_317432 | REC_0016267 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 9.7 | 50 | male | 0 | 14 | 3 | 5 | sotorasib 960 mg daily | 4 | false | MSS | 2026-03-15T05:36:01.669257+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_765110 | REC_0016268 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 6.5 | 63 | male | 1 | 13 | 3.4 | 6 | alectinib 600 mg BID | 10.2 | false | MSS | 2026-03-15T05:36:01.669624+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_361153 | REC_0016269 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 15.2 | 70 | female | 1 | 12 | 4.7 | 6 | sotorasib 960 mg daily | 16.2 | true | MSS | 2026-03-15T05:36:01.669988+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_963661 | REC_0016270 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 9.7 | 68 | male | 0 | 0 | 4.8 | 2 | sotorasib 960 mg daily | 24.3 | true | MSS | 2026-03-15T05:36:01.670344+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_472414 | REC_0016271 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 18 | 10.1 | 71 | female | 3 | 20 | 3.7 | 1 | sotorasib 960 mg daily | 25.1 | true | MSS | 2026-03-15T05:36:01.670716+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_690542 | REC_0016272 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 15 | 16.3 | 67 | female | 0 | 16 | 5.3 | 6 | pembrolizumab 200 mg q3w | 5.2 | true | MSS | 2026-03-15T05:36:01.671175+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_563420 | REC_0016273 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 13.5 | 57 | female | 0 | 22 | 4.4 | 4 | osimertinib 80 mg daily | 7 | false | MSI-H | 2026-03-15T05:36:01.671627+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_502402 | REC_0016274 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 10.2 | 60 | female | 1 | 22 | 8.4 | 2 | alectinib 600 mg BID | 17.5 | true | MSI-H | 2026-03-15T05:36:01.672139+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_827941 | REC_0016275 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 18 | 8.8 | 59 | male | 0 | 17 | 6.2 | 2 | entrectinib 600 mg daily | 19 | false | MSS | 2026-03-15T05:36:01.672613+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_112904 | REC_0016276 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 11.4 | 72 | female | 1 | 12 | 8 | 6 | sotorasib 960 mg daily | 5.6 | true | MSS | 2026-03-15T05:36:01.672986+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_602602 | REC_0016277 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 12.3 | 61 | male | 1 | 22 | 6 | 1 | osimertinib 80 mg daily | 12.1 | false | MSI-H | 2026-03-15T05:36:01.673587+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_386270 | REC_0016278 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 22 | 3.9 | 59 | female | 0 | 10 | 4.1 | 2 | pembrolizumab 200 mg q3w | 18.3 | true | MSS | 2026-03-15T05:36:01.674031+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_989854 | REC_0016279 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 13.1 | 52 | female | 0 | 13 | 7.5 | 6 | osimertinib 80 mg daily | 11.2 | false | MSS | 2026-03-15T05:36:01.674425+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_645235 | REC_0016280 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 9.4 | 50 | female | 0 | 16 | 5.2 | 4 | osimertinib 80 mg daily | 8.7 | false | MSS | 2026-03-15T05:36:01.674756+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_937709 | REC_0016281 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 8.5 | 54 | female | 0 | 15 | 5.4 | 4 | sotorasib 960 mg daily | 6.1 | true | MSS | 2026-03-15T05:36:01.675100+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_868388 | REC_0016282 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 10.3 | 65 | male | 1 | 24 | 6 | 4 | entrectinib 600 mg daily | 10.8 | false | MSI-H | 2026-03-15T05:36:01.675443+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_816137 | REC_0016283 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 14 | 71 | female | 1 | 17 | 6.3 | 6 | entrectinib 600 mg daily | 8.5 | true | MSS | 2026-03-15T05:36:01.675789+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_513005 | REC_0016284 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 9.3 | 58 | female | 0 | 19 | 4.9 | 2 | entrectinib 600 mg daily | 15.9 | false | MSS | 2026-03-15T05:36:01.676215+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_189836 | REC_0016285 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 14.4 | 61 | female | 0 | 22 | 5 | 8 | osimertinib 80 mg daily | 20 | false | MSS | 2026-03-15T05:36:01.676604+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_209669 | REC_0016286 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 7.4 | 49 | female | 0 | 6 | 6.1 | 4 | osimertinib 80 mg daily | 5.8 | true | MSS | 2026-03-15T05:36:01.676984+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_326211 | REC_0016287 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 11.2 | 73 | female | 2 | 19 | 6.8 | 3 | entrectinib 600 mg daily | 5.6 | false | MSI-H | 2026-03-15T05:36:01.677362+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_448827 | REC_0016288 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 7.6 | 73 | female | 1 | 38 | 5.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 14.7 | true | MSS | 2026-03-15T05:36:01.677733+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_873603 | REC_0016289 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 9.3 | 64 | male | 1 | 15 | 3.9 | 2 | sotorasib 960 mg daily | 8 | false | MSS | 2026-03-15T05:36:01.678121+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_731367 | REC_0016290 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 12.6 | 80 | female | 1 | 28 | 4.2 | 2 | osimertinib 80 mg daily | 9 | true | MSS | 2026-03-15T05:36:01.678609+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_736071 | REC_0016291 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 8.2 | 63 | male | 1 | 16 | 5.5 | 6 | entrectinib 600 mg daily | 19.7 | true | MSS | 2026-03-15T05:36:01.678985+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_939680 | REC_0016292 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 6.7 | 66 | female | 0 | 30 | 5.3 | 8 | carboplatin + paclitaxel + pembrolizumab | 9.9 | false | MSS | 2026-03-15T05:36:01.679346+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_900562 | REC_0016293 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 32 | 13.5 | 63 | male | 0 | 24 | 6.9 | 5 | pembrolizumab 200 mg q3w | 14.3 | false | MSS | 2026-03-15T05:36:01.679691+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_528237 | REC_0016294 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 16.6 | 66 | female | 1 | 12 | 4.7 | 6 | entrectinib 600 mg daily | 5.3 | false | MSI-H | 2026-03-15T05:36:01.680036+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_508273 | REC_0016295 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 14 | 10.2 | 64 | female | 1 | 8 | 7.2 | 6 | sotorasib 960 mg daily | 4.4 | false | MSI-H | 2026-03-15T05:36:01.680855+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_903728 | REC_0016296 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 31 | 5.5 | 73 | female | 1 | 36 | 6.5 | 4 | pembrolizumab 200 mg q3w | 13.7 | false | MSS | 2026-03-15T05:36:01.681385+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_791958 | REC_0016297 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 6.5 | 62 | female | 1 | 16 | 7.2 | 2 | alectinib 600 mg BID | 23.2 | false | MSS | 2026-03-15T05:36:01.682070+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_136020 | REC_0016298 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 12.6 | 68 | female | 1 | 9 | 7.1 | 1 | osimertinib 80 mg daily | 17.2 | true | MSI-H | 2026-03-15T05:36:01.682580+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_465672 | REC_0016299 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 9.2 | 70 | female | 1 | 12 | 7.7 | 1 | alectinib 600 mg BID | 29.6 | false | MSS | 2026-03-15T05:36:01.682973+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_574894 | REC_0016300 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 11.3 | 76 | female | 2 | 12 | 2 | 6 | entrectinib 600 mg daily | 14 | false | MSS | 2026-03-15T05:36:01.683356+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.